Laura Dichtel MD

Diabetes, Lipid Metabolism, Pituitary Disorders & Neuroendocrinology

Assistant Professor, Harvard Medical School and Massachusetts General Hospital

55 Fruit St# BUL457Boston, MA 02114
Phone+1 617-724-3614
Fax+1 617-726-5072

Dr. Dichtel is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dichtel's full profile Already have an account?

Education & Training

Mass General Brigham/Massachusetts General HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 2012 - 2015
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2009 - 2012
Yale School of MedicineClass of 2009

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MA State Medical License 2012 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2017
CMS Meaningful Use Stage 1 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2017

Clinical Trials

The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease Start of enrollment: 2022 Aug 10
COMPLETED
PHASE2
Roles: Principal Investigator, Contact

Publications & Presentations

PubMed

Development and characterization of a long-acting allosteric growth hormone receptor antagonist for acromegaly.
Katherine Kurylo, Page R Bouchard, Mark N Milton, Peter F Moesta, Laura E Dichtel
Endocrinology. 2026-08-03
Introduction. Craniopharyngioma: contemporary management.
Pamela S Jones, Laura E Dichtel, Tareq A Juratli, Kyle C Wu, Olabisi R Sanusi
Neurosurgical Focus. 2026-06-01
Expansion of a physician parental wellness programme at the Massachusetts General Hospital to improve physician well-being.
Josephine H Li, Megan F Hoang, Lauren E Olson, Kerri Palamara, Erin E Sullivan
BMJ Leader. 2025-12-31

Lectures

Neuroendocrinology and Pituitary
ENDO 2019 - New Orleans, LA - 3/25/2019
Optimizing Hormone Treatment in the Hypopituitary Patient (Repeat)
ENDO 2019 - New Orleans, LA - 3/25/2019
Optimizing Hormone Treatment in the Hypopituitary Patient
ENDO 2019 - New Orleans, LA - 3/25/2019

Press Mentions

Top in Endocrinology: Nonalcoholic Fatty Liver Disease in Patients with Obesity, DiabetesJune 29th, 2022
Lumos Pharma, Inc. (LUMO) CEO Richard Hawkins on Q1 2022 Results - Earnings Call TranscriptMay 11th, 2022
Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated TrialMay 5th, 2022

Grant Support

Metabolomic Investigation of the Impact of Growth Hormone on Nonalcoholic Fatty Liver Disease: Identification of Novel Biomarkers and Therapeutic TargetsMASSACHUSETTS GENERAL HOSPITAL2022–2025